News | January 25, 2024
Shilpa Medicare directed to to pay damage to Celltrion
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Automated parallel capillary electrophoresis system simplifies protein analysis
Collaboration streamlines patient access to oncology clinical trials
Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
The Institute is catering the health needs of the surrounding population with ever-increasing OPD every year along with special OPDs like mother & Child OPD, and LSD clinic
HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Subscribe To Our Newsletter & Stay Updated
